Some remarkable results in this study published yesterday in JAMA. This paper strongly suggests that patients’ high-risk nonmetastatic hormone-sensitive prostate cancers are frequently understaged by conventional imaging. The results challenge the interpretation of previous studies, such as the EMBARK trial.
Interested in folks’ comments.